Search En menu en ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages
    Reference: 20120005
    Release date: 26 June 2012

    Promoter – Financial Intermediary

    MERCK KGAA

    Location

    Description

    The project will finance the promoter’s research and development (R&D) expenses for the development of a new cancer treatment. It concerns the clinical programme of a cancer vaccine for indications such as NSCLC (non-small-cell lung cancer), which is the major indication currently investigated, as well as trials for colorectal- , prostate- and breast cancer indications.

    Objectives

    It is the objective of this new cancer vaccine to stimulate the body's immune system to identify and destroy cancer cells.

    Sector(s)

    Proposed EIB finance (Approximate amount)

    EUR 200 million

    Total cost (Approximate amount)

    EUR 625 million

    Environmental aspects

    R&D activities included in the project will not materially change current R&D practice and will be carried out within existing facilities making use of existing laboratories, pilot plants, clinical centres, etc. An Environmental Impact Assessment (EIA) by a competent authority according to the Directive 85/337/EEC, amended by Directives 97/11/EC and 2003/35/EC should not be required.

    Procurement

    The promoter is a private company not operating in the utilities sector, and is thus not covered by EU Directives on procurement.

    Status

    Signed - 16/07/2013

    Disclaimer

    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
    They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Related tags

    Germany Industry